The goal of the High Speed Cell Sorter (HSCS) Core is to provide outstanding cell sorting and analysis service for SCC members. Flow cytometry is an essential tool for basic and translational cancer research. The analytical and preparative platforms in this Core are used to quantify, characterize, and purify cellular populations of interest for in vitro and in vivo studies by Core users. The HSCS Core was established in 2001 and has experienced rapid growth in capacity and utilization over a short period of time.
The Aims of the HSCS Core are as follows:
Aim 1. To develop and maintain flexible platforms for multiparameter cell analysis. Four 5-color and one 8-color benchtop flow cytometric analyzers are available 24/7 for use by cancer center members. Three cell sorters operated by Core staff support more sophisticated analysis involving up to 20 parameters.
Aim 2. To develop and maintain flexible platforms for multiparameter cell sorting. Three cell sorters provide a highly customizable platform that can support high speed sorting on up to 10 simultaneous parameters. Workflow is separated within the Core into three distinct domains for sorting of cells from humans, model organisms, or from potentially biohazardous samples.
Aim 3. To provide additional services that enhance the academic mission of the SCC. The HSCS Core will promote the use of flow cytometry in cancer-related research by providing technical assistance in preparation of cells for sorting or analysis, training personnel on use of flow cytometry instrumentation, and assisting with data archiving, analysis, interpretation, grant writing, and manuscript preparation.

Public Health Relevance

The High Speed Cell Sorter Core uses state-of-the-art instrumentation and highly trained personnel to assist scientists with cell measurements and manipulations that are essential for modern research in cancer biology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA091842-11S1
Application #
8530571
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
11
Fiscal Year
2012
Total Cost
$2,777
Indirect Cost
$950
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Aliev, Fazil; Salvatore, Jessica E; Agrawal, Arpana et al. (2018) A Brief Critique of the TATES Procedure. Behav Genet 48:155-167
Mills, Jason C; Samuelson, Linda C (2018) Past Questions and Current Understanding About Gastric Cancer. Gastroenterology 155:939-944
Salloum, Naji C; Buchalter, Erica Lf; Chanani, Swati et al. (2018) From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. Pharmacogenomics 19:861-871
Dehdashti, Farrokh; Wu, Ningying; Bose, Ron et al. (2018) Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Res Treat 169:523-530
Donabedian, Patrick L; Kossatz, Susanne; Engelbach, John A et al. (2018) Discriminating radiation injury from recurrent tumor with [18F]PARPi and amino acid PET in mouse models. EJNMMI Res 8:59
Shepherd, Andrew J; Copits, Bryan A; Mickle, Aaron D et al. (2018) Angiotensin II Triggers Peripheral Macrophage-to-Sensory Neuron Redox Crosstalk to Elicit Pain. J Neurosci 38:7032-7057
Andley, Usha P; Tycksen, Eric; McGlasson-Naumann, Brittney N et al. (2018) Probing the changes in gene expression due to ?-crystallin mutations in mouse models of hereditary human cataract. PLoS One 13:e0190817
Sáenz, José B; Mills, Jason C (2018) Acid and the basis for cellular plasticity and reprogramming in gastric repair and cancer. Nat Rev Gastroenterol Hepatol 15:257-273
Groves, Andrew P; Gettinger, Katie; Druley, Todd E et al. (2018) Special Therapy and Psychosocial Needs Identified in a Multidisciplinary Cancer Predisposition Syndrome Clinic. J Pediatr Hematol Oncol :
Ostrander, Elizabeth L; Koh, Won Kyun; Mallaney, Cates et al. (2018) The GNASR201C mutation associated with clonal hematopoiesis supports transplantable hematopoietic stem cell activity. Exp Hematol 57:14-20

Showing the most recent 10 out of 1244 publications